Moving to the new facility is intended to enhance Cellvax’s preclinical anti-cancer drug development service offering and satisfy customers’ specific demands by expanding its large animal capabilities.
The new laboratory is located at the Ecole Nationale Veterinaire Alfort (ENVA) on the outskirts of Paris, France. ENVA is veterinary university, created in 1766, and houses more than 1,000 people, including professors, technicians and students, on its 110,000 m² campus.
From the site Cellvax can provide clients with services in a range of animals, including mice, rats, rabbits, dogs and minipigs. Furthermore, moving to ENVA has broadened the range of technical platforms that Cellvax has access to.
The contract research organisation (CRO) can now offer clients scintigraphy, histological analysis, biomarkers, in vivo imaging platforms and magnetic resonance imaging (MRI).
Cellvax is also planning to offer subcutaneous and orthotopic tumour models in animals, in vitro and in vivo angiogenesis models, biodistribution, pharmacokinetics and toxicity services.
The proposed services will be adapted to the validation and development of oncology candidates. Cellvax added that the tests are fully validated. The CRO was established in 2001 and has performed in vitro and in vivo studies for companies in regions including Europe and Israel.
No one from Cellvax was available to answer Outsourcing-Pharma’s questions at the time of publication.